Condition
Unresectable Stage III NSCLC
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 4 (1)
Trial Status
Unknown2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04381494Phase 4TerminatedPrimary
Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.
NCT04982549Phase 2UnknownPrimary
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
NCT04161352UnknownPrimary
Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC
Showing all 3 trials